

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6457348

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NERRE THERAPEUTICS LIMITED	09/08/2020
RECEIVING PARTY DATA	
Name:	KANDY THERAPEUTICS LIMITED
Street Address:	400 SOUTH OAK WAY
City:	READING, BERKSHIRE
State/Country:	UNITED KINGDOM
Postal Code:	RG2 6AD
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	7683056
Patent Number:	7919491
Patent Number:	8097618
Patent Number:	8093242
Patent Number:	8796269
CORRESPONDENCE DATA	
Fax Number:	(626)792-1342
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6267920536
Email:	mail@sbpatlaw.com
Correspondent Name:	STEINFL + BRUNO LLP
Address Line 1:	155 N. LAKE AVE. STE 700
Address Line 4:	PASADENA, CALIFORNIA 91101
ATTORNEY DOCKET NUMBER:	P1176-US, ET AL.
NAME OF SUBMITTER:	ALESSANDRO STEINFL
SIGNATURE:	/ALESSANDRO STEINFL, REG. NO. 56,448/
DATE SIGNED:	12/17/2020
Total Attachments: 4	
source=KAN128520 PCT-US et al._ExecAssignment_NeRRe-to-Kandy_Steinfl#page1.tif	

source=KAN128520 PCT-US et al._ExecAssignment_NeRRe-to-Kandy_Steinfl#page2.tif

source=KAN128520 PCT-US et al._ExecAssignment_NeRRe-to-Kandy_Steinfl#page3.tif

source=KAN128520 PCT-US et al._ExecAssignment_NeRRe-to-Kandy_Steinfl#page4.tif

PATENT

REEL: 054687 FRAME: 0379

CONFIRMATORY ASSIGNMENT

NERRE THERAPEUTICS LIMITED, a company incorporated in England and Wales (registered number 07916206) whose registered office is at Stevenage Bioscience Catalyst, Incubator Building, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX, United Kingdom ("Assignor").

hereby confirms to have sold and assigned with effective date of September 8, 2020 for good and valuable consideration, the receipt of which it hereby acknowledges,

to KANDY THERAPEUTICS LIMITED, a company with address at 400 South Oak Way, Reading, Berkshire, England, RG2 6AD ("Assignee"),

its successors, assigns and nominees, its entire right, title and interest, including all priority rights under U.S. law and/or International conventions and treaties, in and to US Patents 7,683,056 B2 (issued on March 23, 2010), 7,919,491 B2 (issued on April 5, 2011), 8,097,618 B2 (issued on January 17, 2012), 8,093,242 B2 (issued on January 10, 2012) and 8,796,269 B2 (issued on August 5, 2014).

Assignor and Assignee have agreed that all patents set out above together with the inventions disclosed therein and all reissues, reexaminations, divisionals, continuations, continuations-in-part, extensions, supplementary additions and supplementary protection certificates deriving or claiming priority from any of the same or from which any of the same may derive or claim priority are to be assigned absolutely to and for the benefit of Assignee.

FOR ASSIGNOR NERRE THERAPEUTICS LIMITED

Subscribed and executed at Cheltenham UK
On 4 December 2020 City Country
Date

Officer Name: Mary Kerr
Officer Title: CEO
Officer Signature: [Signature]

Witnessed by:

Witness Name: MIKE TROWER Signature: [Signature]

Witness Name: DIANA TROWER Signature: [Signature]

FOR ASSIGNEE KANDY THERAPEUTICS LIMITED

Exercised as a Deed by virtue of powers granted to the signatory by resolution of the Board

at _____
City Country
On _____
Date

Officer Name: _____

Officer Title: Authorized Signatory

Officer Signature: _____

CONFIRMATORY ASSIGNMENT

NERRE THERAPEUTICS LIMITED, a company incorporated in England and Wales (registered number 07916206) whose registered office is at Stevenage Bioscience Catalyst, Incubator Building, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX, United Kingdom ("Assignor").

hereby confirms to have sold and assigned with effective date of September 8, 2020 for good and valuable consideration, the receipt of which it hereby acknowledges,

to KANDY THERAPEUTICS LIMITED, a company with address at 400 South Oak Way, Reading, Berkshire, England, RG2 6AD ("Assignee"),

its successors, assigns and nominees, its entire right, title and interest, including all priority rights under U.S. law and/or International conventions and treaties, in and to US Patents 7,683,056 B2 (issued on March 23, 2010), 7,919,491 B2 (issued on April 5, 2011), 8,097,618 B2 (issued on January 17, 2012), 8,093,242 B2 (issued on January 10, 2012) and 8,796,269 B2 (issued on August 5, 2014).

Assignor and Assignee have agreed that all patents set out above together with the inventions disclosed therein and all reissues, reexaminations, divisionals, continuations, continuations-in-part, extensions, supplementary additions and supplementary protection certificates deriving or claiming priority from any of the same or from which any of the same may derive or claim priority are to be assigned absolutely to and for the benefit of Assignee.



FOR ASSIGNOR NERRE THERAPEUTICS LIMITED

Subscribed and executed at _____

City

Country

On _____

Date

Officer Name: _____

Officer Title: _____

Officer Signature _____

Witnessed by:

Witness Name: _____ Signature _____

Witness Name: _____ Signature _____

FOR ASSIGNEE KANDY THERAPEUTICS LIMITED

Exercised as a Deed by virtue of powers granted to the signatory by resolution of the Board

At

Monheim
City

Germany
Country

On 8 Dec 2020
Date

Officer Name: Dr. Alexander Nowak

Officer Title: Authorized Signatory

Officer Signature _____
